E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
Fearon (2017)
Urinary cotinine levels of electronic cigarette (e-cigarette) users
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
Goney (2016)
Computational analysis of deposition and translocation of inhaled nicotine and acrolein in the human body with e-cigarette puffing topographies
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
Haghnegahdar (2018)
Combined analysis of N′-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in the urine of cigarette smokers and e-cigarette users
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
Kotandeniya (2015)
Nicotine Blood Levels and Short-term Smoking Reduction with an Electronic Nicotine Delivery System
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
Nides (2014)
Monitoring nicotine intake from e-cigarettes: measurement of parent drug and metabolites in oral fluid and plasma
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
Papaseit (2017)
Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
St. Helen (2016)
Urinary concentrations of monohydroxylated polycyclic aromatic hydrocarbons in adults from the U.S. Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013–2014)
Individual Clinical
Pharmacokinetics
& Abuse Liability
Pharmacokinetics
Wang (2019)
Electronic nicotine delivery systems (ENDS) aerosol constituent deposition and nicotine retention in the human oral cavity.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
asgharian (2023)
Simulation Modeling of air and Droplet Temperatures in the human Respiratory Tract for Inhaled Tobacco Products.
Individual Clinical
Pharmacokinetics & Abuse Liability
Pharmacokinetics
asgharian (2023)